<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643939</url>
  </required_header>
  <id_info>
    <org_study_id>RENOVATEmain_2018_08</org_study_id>
    <nct_id>NCT03643939</nct_id>
  </id_info>
  <brief_title>High-Flow Nasal Oxygen Cannula Compared to Non-Invasive Ventilation in Adult Patients With AcuTE Respiratory Failure</brief_title>
  <acronym>RENOVATE</acronym>
  <official_title>RandomizEd Adaptive Trial of High-Flow Nasal Oxygen Cannula Compared to Non-Invasive Ventilation for AcuTE Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berry Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RENOVATE study aims to investigate if the respiratory support device called High-Flow Nasal
      Oxygen Cannula (HFNC) acts similarly (non-inferior) to another respiratory support device
      called Non-Invasive positive-pressure Ventilation (NIPPV) in preventing endotracheal
      intubation in adult patients with Acute Respiratory Failure (ARF) from different causes. HFNC
      is a somewhat new method of respiratory support in adults that has been used in neonatal ARF
      for some years. The reason this study is necessary is that, even though NIPPV has been
      demonstrated to prevent endotracheal intubation (and its associated complications) in a broad
      range of ARF patients, HFNC has been proposed to have the same beneficial effect of NIPPV
      while being easier tolerated, allowing patients to talk, eat and drink through mouth while on
      HFNC. RENOVATE will recruit between 800 to 2000 patients (adaptive design) with different
      types of ARF in Brazil. Patients will be randomized to HFNC or NIPPV and the rate of
      endotracheal intubation will be compared between groups as well as other parameters such as
      vital status and other health care related complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adaptive, non-inferiority randomized, open-label, controled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endotracheal intubation rate</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IMV free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>truncated at 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>truncated at 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vasopressor free days</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Renal replacement therapy free days</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Respiratory Insufficiency</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>High Flow Nasal Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The HFNC (AIRVO2 Fisher &amp; Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-invasive positive pressure ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or invasive mechanical ventilator with NIPPV mode are accepted. The interface should be a oronasal or full face mask.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal Catheter</intervention_name>
    <description>HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.
Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patientÂ´s comfort and SpO2.</description>
    <arm_group_label>High Flow Nasal Catheter</arm_group_label>
    <other_name>Optiflow</other_name>
    <other_name>Airvo</other_name>
    <other_name>trans-nasal insufflation</other_name>
    <other_name>Nasal High Flow</other_name>
    <other_name>High Flow Nasal Cannula</other_name>
    <other_name>nasal cannula with high-flow oxygen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Noninvasive ventilation</intervention_name>
    <description>NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol</description>
    <arm_group_label>Non-invasive positive pressure ventilation</arm_group_label>
    <other_name>BiPAP</other_name>
    <other_name>Non-invasive ventilation</other_name>
    <other_name>Noninvasive positive pressure ventilation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Sequential adult patients 18 years of age or older admitted to the ICU or emergency
        department with acute onset respiratory distress suspected of having De Novo hypoxemic ARF
        (non-immunocompromised) , Immunocompromised De Novo hypoxemic ARF, COPD ARF, Cardiogenic
        acute pulmonary edema (APE).

        Inclusion criteria for these 4 ARF subgroups are detailed below:

        A. Inclusion Criteria for Non-Immunocompromised De Novo Hypoxemic ARF.

        Patients must meet criteria 1, 2 and 3:

          1. Hypoxemia evidenced by SpO2 &lt;90% or PaO2 &lt;60 mmHg in room air

          2. Use of accessory muscles, paradoxical breathing, and/or thoracoabdominal asynchrony

          3. RR&gt; 25 per minute

        B. Inclusion Criteria for Immunocompromised De Novo Hypoxemic ARF.

        Patients must meet criteria 1, 2, 3 and 4:

          1. Immunosuppression diagnosis:

             i. Use of Immunosuppressive drug or long-term [&gt;3 months] or high-dose [&gt;0.5
             mg/kg/day] steroids ii. Solid organ transplantation iii. Extensive solid tumor or
             solid tumor requiring chemotherapy in the last 5 years iv. Hematological malignancy
             regardless of time since diagnosis and received treatments v. HIV infection vi.
             Primary immunodefiency

          2. Hypoxemia evidenced by SpO2 &lt;90% or PaO2 &lt;60 mmHg in room air

          3. Use of accessory muscles, paradoxical breathing, and/or thoracoabdominal asynchrony

          4. RR&gt; 25 per minute

        C. Inclusion Criteria for COPD exacerbation:

        Patients must meet criteria 1 or 2 and 3 and 4:

          1. Previous Diagnosis of COPD based on GOLD guidelines

          2. Strong clinical suspicion of COPD i. Smoker or ex-smoker or other CPOD related
             exposure ii. Presence of chronic dyspnea on exertion or chronic productive cough iii.
             Excluded other causes for the chronic symptoms (ex. pulmonary fibrosis, heart failure)

          3. RR&gt; 25 per minute or use of accessory muscles, paradoxical breathing, and/or
             thoracoabdominal asynchrony

          4. ABG analysis with pH &lt; 7,35 , paCO2&gt; 45 mmHg

        D. Inclusion Criteria for ARF secondary to Cardiogenic APE.

        Patients must meet criteria numbers 1, 2 and 3:

          1. Diagnosis of Cardiogenic Acute Pulmonary Edema (Nava, 2003):

             i. Dyspnea of sudden onset ii. Widespread rales with or without third heart sound 1
             iii. Absent history of pulmonary aspiration, infection or previous history of
             pulmonary fibrosis iv. Pulmonary edema as the main clinical hypothesis v. Previous
             heart failure clinical history or acute coronary syndrome vi. If chest X-ray is
             already available at randomization, it must be suggestive of bilateral pulmonary edema

          2. RR &gt; 25 per minute

          3. SpO2 &lt; 95%

        Exclusion Criteria for all subgroups of ARF

          1. Indication of emergency ETI:

               -  Prolonged respiratory pauses

               -  Cardiorespiratory arrest

               -  Glasgow â¤12

               -  HR &lt; 50 bpm with decreased level of consciousness

               -  pH &lt; 7.15 irrespective of the cause

          2. Psychomotor agitation that prevents adequate medical / nursing care requiring heavy
             sedation

          3. Persistent hemodynamic instability with MAP &lt;65 mmHg, SBP &lt;90 mmHg after adequate
             volume resuscitation or requiring norepinephrine&gt; 0.3 microg / kg / min or equivalent.

          4. Contraindications to non-invasive ventilation: face deformities or traumas, recent
             esophageal surgery, hypersecretion, vomiting with aspiration risk

          5. Presence of pneumothorax or extensive pleural effusion

          6. Severe arrhythmias at risk of hemodynamic instability

          7. Thoracic trauma understood as the main cause of ARF

          8. Asthma attack

          9. Pregnancy

         10. Cardiogenic Shock

         11. Acute Coronary Syndromes with plans to undergo coronary angiography within 24 hs

         12. ARF after orotracheal extubation (up to 7 days after extubation)

         13. Post-surgical ARF (surgery within 7 days)

         14. Hypercapnic ARF due to neuromuscular disease or chest deformities

         15. Patients on exclusive palliative care

         16. Do Not Intubate order (DNI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre B Cavalcanti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Institute - Hospital do Coracao, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Israel Maia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute - Hospital do Coracao, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leticia Kawano-Dourado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute - Hospital do Coracao, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Brochard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Michael's Hospital (Toronto, Canada)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos R Carvalho, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pulmonary Division University of Sao Paulo, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Israel Maia, MD</last_name>
    <phone>+55 11 30536611</phone>
    <phone_ext>8209</phone_ext>
    <email>israels.maia@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leticia Kawano-Dourado, MD</last_name>
    <phone>+55 11 30536611</phone>
    <phone_ext>8209</phone_ext>
    <email>ldourado@hcor.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital do Coracao</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>05435000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Romano, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Luzia Taniguchi, MSc</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>respiratory insufficiency</keyword>
  <keyword>respiratory failure</keyword>
  <keyword>non-invasive ventilation</keyword>
  <keyword>high flow nasal cannula</keyword>
  <keyword>nasal high flow</keyword>
  <keyword>trans-nasal insufflation</keyword>
  <keyword>NIV</keyword>
  <keyword>HFNC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

